Global Pharma and Biotech Summit
Biopharmaceutical businesses are striving to innovate and achieve growth amid relentless disruption. Breakthroughs in precision medicine and obesity treatments are reshaping healthcare. AI is predicted to drive discovery of 30 percent of new drugs this year. Industry leaders and start-ups are collaborating and competing to develop the next blockbuster. But sustainable growth is threatened by factors such as regulatory divergence, overburdened health systems and geopolitical risk.
The Global Pharma and Biotech Summit is the essential event for you to explore era-defining trends and developments in healthcare and life sciences. Distinguished innovators, investors and C-suite executives will discuss what’s new in key areas such as drug discovery, clinical trials, market access and patient engagement.
Snapshot of our 2025 Speakers
Why Attend?
Understand
the technology and innovation behind new treatments with the power to transform healthcare.
Connect
with industry leaders responsible for the big decisions in areas such as investment, innovation and market access.
Discover
new ideas to support business transformation and maximise return on investment.
THE SUPER EARLY BIRD
IN-PERSON PASS
Gain access to in-person sessions and networking drinks. Network and connect with your peers.
£2,899
Full price £4,199 from 26 April 2026
THE SUPER EARLY BIRD
DIGITAL PASS
Access to live talks, Q&A and video on demand. Join from the comfort of your home or office.
£219
Full price £479 from 12 April 2026
Key themes
Geopolitical and Economic Disruptions:
The escalating political and economic tension between the US and China raises concerns about strategic de-coupling, affecting global R&D, manufacturing, and market access.
The Rise of New Pharma Powers:
India is recognised as a rapidly growing biotech hub, maturing beyond generic drugs and China is transitioning from a licensing market to a global innovation force.
Regulation of Emerging Technologies:
Regulators face challenges assessing complex technologies with limited transparency. Defining "evidence" in the context of AI and RWE is also a concern.
Drug Pricing and Reimbursement Pressures:
Balancing drug affordability with the need to fund innovation is a central challenge.
Patient Empowerment and Digital Health:
Apps, sensors, and digital platforms are reshaping patient interactions with therapies.
"I learned so much. We heard from practising doctors, government payers... Putting that spectrum together has been incredibly educational for me and really helpful for our practice" - Seth Ettenberg, President and CEO, BlueRock Therapeutics
More Events in our Series
Speaking Opportunities
Ben Graham
ben.graham@ft.com
Sponsorship
Holly Watson-Steward
holly.watson-steward@ft.com
Delegate Services
Hauwra Sharif
hauwra.sharif@ft.com